Evidence map›Paper›PMID 29319470›Full record

ArticleMicrobial genomics2018

Coupling next-generation sequencing to dominant positive screens for finding antibiotic cellular targets and resistance mechanisms in Escherichia coli.

Hélène Gingras, Bédis Dridi, Philippe Leprohon, Marc Ouellette

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Microbial genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hélène GingrasCentre de Recherche en Infectiologie, Université Laval, Québec, Canada.
Bédis DridiCentre de Recherche en Infectiologie, Université Laval, Québec, Canada.
Philippe LeprohonCentre de Recherche en Infectiologie, Université Laval, Québec, Canada.
Marc OuelletteCentre de Recherche en Infectiologie, Université Laval, Québec, Canada.
Université Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to expedite the discovery of genes coding for either drug targets or antibiotic resistance, we have developed a functional genomic strategy termed Plas-Seq. This technique involves coupling a multicopy suppressor library to next-generation sequencing. We generated an Escherichia coli plasmid genomic library that was transformed into E. coli. These transformants were selected step by step using 0.25× to 2× minimum inhibitory concentrations for ceftriaxone, gentamicin, levofloxacin, tetracycline or trimethoprim. Plasmids were isolated at each selection step and subjected to Illumina sequencing. By searching for genomic loci whose sequencing coverage increased with antibiotic pressure we were able to detect 48 different genomic loci that were enriched by at least one antibiotic. Fifteen of these loci were studied functionally, and we showed that 13 can decrease the susceptibility of E. coli to antibiotics when overexpressed. These genes coded for drug targets, transcription factors, membrane proteins and resistance factors. The technique of Plas-Seq is expediting the discovery of genes associated with the mode of action or resistance to antibiotics and led to the isolation of a novel gene influencing drug susceptibility. It has the potential for being applied to novel molecules and to other microbial species.

Indexed as

Anti-Bacterial AgentsCeftriaxoneCRISPR-Cas SystemsDNA-Binding ProteinsDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli ProteinsGene Knockdown TechniquesGenes, BacterialGentamicinsHigh-Throughput Nucleotide SequencingLevofloxacinMembrane ProteinsMicrobial Sensitivity TestsPlasmidsR FactorsAnti-Bacterial AgentsCeftriaxoneDNA-Binding ProteinsEscherichia coli ProteinsGentamicinsLevofloxacinMembrane ProteinsRob protein, E coliTetracyclineTranscription FactorsTrimethoprimantibioticdrug targetsEscherichia colifunctional cloningnext generation sequencingresistance

Identifiers

PMID29319470
PMCPMC5857375
OpenAlexW2783442164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.